7-羟基-3,4-二氢-1(2H)-喹啉羧酸叔丁酯 | 676254-89-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 7-羟基-3,4-二氢-1(2H)-喹啉羧酸叔丁酯
• 中文别名: 7-羟基-3,4-二氢喹啉-1(2H)-羧酸叔丁酯
• 英文名称: 7-hydroxy-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 7-hydroxy-3,4-dihydroquinoline-1(2H)-carboxylate；tert-butyl 7-hydroxy-3,4-dihydro-2H-quinoline-1-carboxylate
• CAS: 676254-89-0
• 化学式: C₁₄H₁₉NO₃
• 分子量: 249.31
• InChiKey: OVLDUSVFVMFMPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-羟基-3,4-二氢-1(2H)-喹啉羧酸叔丁酯 在 盐酸 、 caesium carbonate 、 三乙胺 、 potassium iodide 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 [7-(3-piperidin-1-yl-propoxy)-3,4-dihydro-2H-quinolin-1-yl]-thiophen-2-ylmethanone
  参考文献：
  名称：

  Synthesis and SAR of novel histamine H3 receptor antagonists

  摘要：

  The synthesis and biological evaluation of novel tetrahydroisoquinoline, tetrahydroquinoline, and tetrahydroazepine antagonists of the human and rat H-3 receptors are described. The substitution around these rings as well as the nature of the substituent on nitrogen is explored. Several compounds with high affinity and selectivity for the human and rat H-3 receptors are reported. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.004
• 作为产物：
  描述：

  7-甲氧基-1,2,3,4-四氢喹啉 在 sodium hydroxide 、 三溴化硼 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 7-羟基-3,4-二氢-1(2H)-喹啉羧酸叔丁酯
  参考文献：
  名称：

  Synthesis and SAR of novel histamine H3 receptor antagonists

  摘要：

  The synthesis and biological evaluation of novel tetrahydroisoquinoline, tetrahydroquinoline, and tetrahydroazepine antagonists of the human and rat H-3 receptors are described. The substitution around these rings as well as the nature of the substituent on nitrogen is explored. Several compounds with high affinity and selectivity for the human and rat H-3 receptors are reported. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.004

文献信息

• SUBSTITUTED-2-IMIDAZOLES
  申请人：Galley Guido

  公开号：US20080113980A1

  公开（公告）日：2008-05-15

  The present invention relates to compounds of formula I wherein R 1 is selected from the group consisting of hydrogen and lower alkyl; each R 2 is independently selected from the group consisting of hydrogen and lower alkyl; each R 3 is independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyloxy, benzyloxy, halogen and lower alkyl substituted by halogen; X is selected from the group consisting of —CH 2 —, —CH— and —O—; Y is selected from the group consisting of —CH 2 —, —CH— and a bond with the proviso that, when X is —O—, Y may not be a bond; Z is selected from the group consisting of —CH 2 — and —CH—; m is 0, 1 or 2; and n is 0, 1 or 2; and to pharmaceutically-acceptable acid addition salts of such compounds. The invention relates also to processes for preparing such compounds, compositions comprising such a compound or a pharmaceutically-acceptable acid addition salt thereof, and a method of treating a disease or disorder in a patient comprising administering such a compound, or pharmaceutically-acceptable acid addition salt thereof, to a patient in need of such treatment.

  本发明涉及公式I的化合物，其中R1选择自氢和较低烷基的群体；每个R2独立选择自氢和较低烷基的群体；每个R3独立选择自氢、较低烷基、较低烷氧基、苯氧基、苯甲氧基、卤素和被卤素取代的较低烷基的群体；X选择自—CH2—、—CH—和—O—的群体；Y选择自—CH2—、—CH—和键的群体，但当X为—O—时，Y不能是键；Z选择自—CH2—和—CH—的群体；m为0、1或2；n为0、1或2；以及该类化合物的药学上可接受的酸盐。本发明还涉及制备这种化合物的方法、包含这种化合物或其药学上可接受的酸盐的组合物，以及一种治疗患者疾病或障碍的方法，包括将这种化合物或其药学上可接受的酸盐用于需要此类治疗的患者的治疗中。
• Histamine h3 receptor antagonists, preparation and therapeutic uses
  申请人：Beavers Selsam Lisa

  公开号：US20060167046A1

  公开（公告）日：2006-07-27

  The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-II3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods or using them to treat obesity and other histamine II3 receptor-related diseases.

  本发明揭示了化合物(I)或其药学上可接受的盐的新型化合物，其具有组胺H3受体拮抗活性，以及制备这些化合物的方法。在另一实施例中，本发明揭示了包括化合物(I)的药物组合物，以及使用它们治疗肥胖症和其他组胺H3受体相关疾病的方法。
• SUBSTITUTED 4-IMIDAZOLES
  申请人：Galley Guido

  公开号：US20080139533A1

  公开（公告）日：2008-06-12

  The present invention relates to a compound of formula I, wherein R 1 is selected from the group consisting of hydrogen and lower alkyl; each R 2 is independently selected from the group consisting of hydrogen and lower alkyl; each R 3 is independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyloxy, benzyloxy, halogen and lower alkyl substituted by halogen; R 4 is selected from the group consisting of hydrogen and lower alkyl; X is selected from the group consisting of —CH 2 —, —CH— and —O—; Y is selected from the group consisting of —CH 2 —, —CH 2 CH 2 —, —CH— and a bond; with the proviso that, when X is —O—, Y is —CH 2 —; Z is selected from the group consisting of —CH 2 — and —CH—; m is 1 or 2; and n is 1 or 2. The invention relates also to a pharmaceutically-acceptable acid-addition salt of such a compound, methods for making the compound, and a composition comprising such a compound. It has been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1.

  本发明涉及一种化合物式I，其中R1选自氢和低碳基的群组；每个R2独立地选自氢和低碳基的群组；每个R3独立地选自氢、低碳基、低烷氧基、苯氧基、苄氧基、卤素和被卤素取代的低碳基的群组；R4选自氢和低碳基的群组；X选自—CH2—、—CH—和—O—的群组；Y选自—CH2—、—CH2CH2—、—CH—和键的群组；但当X为—O—时，Y为—CH2—；Z选自—CH2—和—CH—的群组；m为1或2；n为1或2。本发明还涉及该化合物的药学可接受的酸加成盐、制备该化合物的方法和包含该化合物的组合物。已经发现，式I化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。
• Substituted 4-imidazoles
  申请人：Hoffmann-La Roche Inc.

  公开号：US07858652B2

  公开（公告）日：2010-12-28

  The present invention relates to a compound of formula I, wherein R1 is selected from the group consisting of hydrogen and lower alkyl; each R2 is independently selected from the group consisting of hydrogen and lower alkyl; each R3 is independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyloxy, benzyloxy, halogen and lower alkyl substituted by halogen; R4 is selected from the group consisting of hydrogen and lower alkyl; X is selected from the group consisting of —CH2—, —CH— and —O—; Y is selected from the group consisting of —CH2—, —CH2CH2—, —CH— and a bond; with the proviso that, when X is —O—, Y is —CH2—; Z is selected from the group consisting of —CH2— and —CH—; m is 1 or 2; and n is 1 or 2. The invention relates also to a pharmaceutically-acceptable acid-addition salt of such a compound, methods for making the compound, and a composition comprising such a compound. It has been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1.

  本发明涉及一种化合物I，其中R1选自氢和低级烷基组成的群；每个R2独立地选自氢和低级烷基组成的群；每个R3独立地选自氢、低级烷基、低级烷氧基、苯氧基、苄氧基、卤素和被卤素取代的低级烷基组成的群；R4选自氢和低级烷基组成的群；X选自—CH2—、—CH—和—O—组成的群；Y选自—CH2—、—CH2CH2—、—CH—和一个键组成的群；但当X为—O—时，Y为—CH2—；Z选自—CH2—和—CH—组成的群；m为1或2；n为1或2。本发明还涉及这种化合物的药学可接受的酸加成盐、制备该化合物的方法以及包含该化合物的组合物。已经发现，化合物I对追踪胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。
• Substituted-2-imidazoles
  申请人：Hoffman-LaRoche Inc.

  公开号：US07834044B2

  公开（公告）日：2010-11-16

  The present invention relates to compounds of formula I wherein R1 is selected from the group consisting of hydrogen and lower alkyl; each R2 is independently selected from the group consisting of hydrogen and lower alkyl; each R3 is independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyloxy, benzyloxy, halogen and lower alkyl substituted by halogen; X is selected from the group consisting of —CH2—, —CH— and —O—; Y is selected from the group consisting of —CH2—, —CH— and a bond with the proviso that, when X is —O—, Y may not be a bond; Z is selected from the group consisting of —CH2— and —CH—; m is 0, 1 or 2; and n is 0, 1 or 2; and to pharmaceutically-acceptable acid addition salts of such compounds. The invention relates also to processes for preparing such compounds, compositions comprising such a compound or a pharmaceutically-acceptable acid addition salt thereof, and a method of treating a disease or disorder in a patient comprising administering such a compound, or pharmaceutically-acceptable acid addition salt thereof, to a patient in need of such treatment.

  本发明涉及式I的化合物，其中R1选自氢和较低的烷基组；每个R2独立地选自氢和较低的烷基组；每个R3独立地选自氢、较低的烷基、较低的烷氧基、苯氧基、苄氧基、卤素和被卤素取代的较低烷基；X选自-CH2-、-CH-和-O-组；Y选自-CH2-、-CH-和键，但当X为-O-时，Y不能是键；Z选自-CH2-和-CH-组；m为0、1或2；n为0、1或2；以及这些化合物的药学可接受的酸加盐。本发明还涉及制备这些化合物的方法，包含这样的化合物或其药学可接受的酸加盐的组合物，以及通过向需要此类治疗的患者施用这种化合物或其药学可接受的酸加盐来治疗患病或障碍的方法。